Netherlands· NL-ed62e93ab8a5
MabThera 1600 mg oplossing voor subcutane injectie
A medicinal product containing rituximab, registered in Netherlands by Roche Registration GmbH.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- RITUXIMAB
- Manufacturer
- Roche Registration GmbH
- Country
- Netherlands (NL)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/98/067
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Rituximab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IrelandMabThera 1600 mg concentrate for solution for infusionRoche Registration GmbH
- FinlandBlitzimaCelltrion Healthcare Hungary Kft.
- United KingdomItuxredi 100mg/10ml concentrate for solution for infusion vialsDr Reddy's Laboratories (UK) Ltd
- CzechiaBLITZIMACelltrion Healthcare Hungary Kft., Budapest
- BelgiumBlitzima 100 mgCelltrion Healthcare Hungary
- SwedenBlitzima 100 mg Koncentrat till infusionsvätska, lösningCelltrion Healthcare Hungary Kft
- IcelandBlitzimaCelltrion Healthcare Hungary Kft.
- PolandBlitzimaCelltrion Healthcare Hungary Kft.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Ituxredi
- Iceland · Blitzima, Mabthera
- Liechtenstein · Blitzima, Mabthera
- Norway · Blitzima, Mabthera
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2d662ee2-f482-49a8-91b5-7d9086215db7 GET /v1/drugs/2d662ee2-f482-49a8-91b5-7d9086215db7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Subcutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_nl.pdf",
"strength": null,
"atc_label": null,
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp116521",
"excipients": [
"HISTIDINE, (L-)",
"HISTIDINEMONOHYDROCHLORIDE 1-WATER (L-)",
"HYALURONIDASE PH20, HUMAAN, RECOMBINANT",
"METHIONINE, (L-)",
"POLYSORBAAT 80 (E 433)",
"TREHALOSE (Alpha, Alpha-) 2-WATER",
"WATER VOOR INJECTIE"
],
"substances": [
"RITUXIMAB"
],
"leaflet_url": null,
"authorised_at": "2016/05/26",
"procedure_number": "EMEA/H/C/000165",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/98/067",
"additional_monitoring": "N"
}See everything about rituximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.